Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRAon October 20, 2019 at 10:00 pm
Pratteln, Switzerland, October 21, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has informed ReveraGen BioPharma about ...
- Press Release: Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRAon October 20, 2019 at 10:00 pm
results in a persistent improvement of muscle function with less adverse effects typically reported for traditional corticosteroids [1-6]. Vamorolone has been granted Orphan Drug status in the US and ...
- San Diego teen gets the surprise of his lifetime as he fights Duchenne muscular dystrophyon October 19, 2019 at 2:35 am
Instead, they were greeted by a crowd of people and a huge surprise. Squeo told the teenager, who was diagnosed with Duchenne Muscular Dystrophy seven years ago, “We're flying your family on an ...
- Parent Project Muscular Dystrophy Announces Arkansas Children's Hospital as Their 28th Certified Duchenne Care Centeron October 17, 2019 at 5:47 pm
Since 2014, Leading Duchenne Organization Has Certified Outstanding Clinics that Provide Optimal Care for People with Duchenne Muscular Dystrophy HACKENSACK, N.J., Oct. 17, 2019 /PRNewswire/ -- Parent ...
- Lack of muscular dystrophy awareness a major concernon October 17, 2019 at 3:55 pm
“The most common form of the disorder that affects children in Andhra is Duchenne Muscular Dystrophy (DMD) which is more serious compared to other forms. However, a majority of patients ...
- Nonprofit CureDuchenne Launches Biobank to Fuel Research for Duchenne Muscular Dystrophyon October 12, 2019 at 11:17 am
CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (Duchenne), announced today it has ...
- Who was Martin Bashir’s brother Tommy and what is Duchenne muscular dystrophy?on October 12, 2019 at 8:43 am
And that is my motivation’.” Martin reveals to Simon and judges Nicole Scherzinger and Louis Walsh that Tommy was born with Duchenne muscular dystrophy. And the interviewer becomes emotional on stage ...
- Novel Gene Therapy for Duchenne Muscular Dystrophy Shows Promiseon October 9, 2019 at 5:32 am
A gene therapy being developed to treat Duchenne muscular dystrophy (DMD) successfully and safely stopped the severe muscle deterioration associated with the rare, genetic disease in both small and ...
- Community pitches in to build house for 23-year-old with muscular dystrophyon October 8, 2019 at 9:06 pm
Alex's family is building the 23-year-old a house so he can finally have the life he wants, one of independence, and that door is key. Alex has Duchenne muscular dystrophy, a disorder which restricts ...
- Muscular dystrophy gene therapy at Penn shows promise in mice, dogson October 7, 2019 at 9:48 am
For a disease with grim consequences that strikes a lot of children, it is hard to top Duchenne muscular dystrophy. Each year, at least 400 new cases are diagnosed in the United States, nearly all of ...
via Bing News